16205-98-4

Usage

Uses

Used in Pharmaceutical Industry:
3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96 is used as a key intermediate in the synthesis of various pharmaceutical compounds. It plays a crucial role in the preparation of 9-(4-chlorobenzoyl)-6-methoxy-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid by reacting with 4-chloro-N-(4-methoxyphenyl)benzohydrazide hydrochloride via Fischer indolization. This reaction is significant in the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96 is also used as a versatile building block in the synthesis of various organic compounds. Its cyclic structure and keto functionality make it a valuable component in the creation of complex molecules for a wide range of applications, including materials science, agrochemicals, and specialty chemicals.

InChI:InChI=1/C7H10O3/c8-6-3-1-2-5(4-6)7(9)10/h5H,1-4H2,(H,9,10)

Upstream product

• 930-68-7 cyclohexenone 
• 124-38-9 carbon dioxide 
• 10265-39-1 7,7-dimethoxynorbornan-2-one 
• 21531-47-5 3-oxo-cyclohexanecarboxylic acid methyl ester 
• 81143-49-9 2-Cyan-3-oxo-1-cyclohexancarbonsaeure-ethylester 
• 586-38-9 3-Methoxybenzoic acid 
• 157163-31-0 2-acetoxy-1,4-diethoxycarbonylcyclohex-1-ene 
• 64-17-5 ethanol 
• 7664-41-7 ammonia 
• 7647-01-0 hydrogenchloride 
• 72453-13-5 2-oxo-cyclohexane-1,4-dicarboxylic acid diethyl ester 
• 17983-30-1 (RS)-3-oxocyclohexanecarbonitrile 
• 99-06-9 3-Carboxyphenol 
• 606488-94-2 3-hydroxycyclohexane-1-carboxylic acid 

Downstream Products

• 33668-25-6 ethyl 3-oxocyclohexanecarboxylate 
• 100911-35-1 3-semicarbazono-cyclohexanecarboxylic acid 
• 39090-68-1 3-hydroxyimino-cyclohexanecarboxylic acid 
• 123364-13-6 3-(chloroacetyl)cyclohexanone 
• 21531-47-5 3-oxo-cyclohexanecarboxylic acid methyl ester 
• 861859-00-9 3-oxo-cyclohexanecarboxylic acid 2-trimethylsilanyl-ethyl ester 
• 37964-14-0 1,2,3,4-Tetrahydro-carbazol-2-carbonsaeure 
• 131404-30-3 Nα-(3-oxocyclohexanecarbonyl)-L-histidyl-L-prolinamide 
• 246-99-1 cyclopenta[b]indole 
• 942-01-8 1,2,3,4-tetrahydrocarbazole 
• 123762-08-3 3-oxocyclohexanecarboxylic acid benzyl ester 
• 1157578-72-7 3-((R)-1-naphthalen-1-yl-ethylamino)-cyclohexanecarboxylic acid 
• 1296113-72-8 9-(3-chloro-phenyl)-1,4-dioxa-9-aza-dispiro[4.1.4.3]tetradecan-8-one 
• 1296113-77-3 7-[2-(3-chloro-phenylamino)-ethyl]-1,4-dioxa-spiro[4.5]decane-7-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

Identification and Implementation of Biocatalytic Transformations in Route Discovery: Synthesis of Chiral 1,3-Substituted Cyclohexanone Building Blocks

Several biocatalytic approaches for the preparation of optically pure methyl 3-oxocyclohexanecarboxylates (S)-, (R)-1 and 3-oxocyclohexanecarbonitriles (S)-, (R)-2 have been successfully demonstrated. Screening of reaction-focused enzyme collections was used to identify initial hits using three enzymatic strategies. Reaction optimization and scale-up enabled the production of chiral intermediates for route scouting efforts on scales of up to 100 g. The enzymes applied in these processes (lipases, enoate reductases, and nitrilases) have been shown to be robust catalysts for drug manufacturing and represent a green alternative to conventional methods to access these chiral cyclohexanone building blocks.

IRAK INHIBITORS AND USES THEREOF

The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same.

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

A catalytic enantioselective conjugate addition of cyanide to enones

The first synthetically useful catalytic enantioselective conjugate addition of cyanide to enones is described. The optimized conditions involved a Gd catalyst (5 or 10 mol %) derived from ligands 3 or 4 and a 1:1 ratio of TBSCN and 2,6-dimethylphenol. Th

Formaldehyde dialkylhydrazones as neutral formyl anion and cyanide equivalents: Nucleophilic addition to conjugated enones

A versatile methodology for the nucleophihc formylation and cyanation of conjugated enones is reported. The procedure is based on the use of formaldehyde dimethylhydrazone, which, acting as a neutral formyl anion equivalent, adds to preformed trialkylsilyl-enone complexes. Both 4-(silyl- oxy)-3-enal hydrazones 3 or deprotected 4-oxo aldehyde monohydrazones 4 can be obtained at products depending on quenching conditions. In full analogy, an asymmetric version of the reaction using chiral formaldehyde SAMP- hydrazone as a neutral synthon of the chiral formyl anion has been developed, giving rise to the corresponding adducts 5 and 6 in good yields and with excellent diastereoselectivities (de 85-≤98%). Ozonolysis or HCl-mediated hydrolysis of adducts 4 and 6 readily affords racemic and optically enriched 4-oxo aldehydes 7, respectively. Additionally, high-yielding MMPP-oxidative cleavage of 4-oxo hydrazones 4 and 6 has been performed to obtain 4-oxo nitriles 8 in racemic and optically enriched forms, respectively. In this way, interesting chiral bifunctional building blocks, some of them bearing newly created stereogenic quaternary centers, have been efficiently synthesized.

2,3-Donor-Acceptor-Substituted 1,3-Butadienes. Synthesis by SO2-Extrusion from 3-Sulfolenes and Diels-Alder Reactions

The thermal extrusion of SO2 from disubstituted 3-sulfolenes 3 leads to 2,3-donor-acceptor-substituted 1,3-butadienes 4.These dienes react with acrylic acid ester and ethyl vinyl ether to the corresponding Diels-Alder adducts 5 and 6 and with themseleves